Abstract: The incidence of prostate cancer increases with age and because of its high prevalence this disease has become a major public health concern. Despite advances in our understanding of the biological mechanisms responsible for the development of this cancer, the transition to the hormone refractory stage (HRPC) and metastatic progression pose real problems of clinical management. Currently, docetaxel chemotherapy has been shown to have a slight but significant impact on survival, though the gain in median survival is still less than three months. Research is therefore continuing to improve treatment outcomes. The progression of prostate cancer is accompanied by the overexpression of EGFR (epidermal growth factor receptor) in a very large majority of cases, suggesting that this may play a mechanistic role. Unfortunately, although preclinical findings seem to be promising for therapies targeting the EGFR in HRPC, current clinical results are disappointing. These results should however encourage us to look for different ways of using anti-EGFR agents or combining them with other targeted therapies.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Guérin, O.; Fischel, J.L.; Ferrero, J.-M.; Bozec, A.; Milano, G. EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment. Pharmaceuticals 2010, 3, 2238-2247.
Guérin O, Fischel JL, Ferrero J-M, Bozec A, Milano G. EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment. Pharmaceuticals. 2010; 3(7):2238-2247.
Guérin, Olivier; Fischel, Jean Louis; Ferrero, Jean-Marc; Bozec, Alexandre; Milano, Gerard. 2010. "EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment." Pharmaceuticals 3, no. 7: 2238-2247.